LPA and metabolic dysfunction-associated steatotic liver disease: These findings corroborate to our study on the association of Lp(a) with new-onset T2D and NAFLD in the context of statin use, and to adjust for triglycerides when examining the association of Lp(a) with T2D and NAFLD.